Predictive role of HPGD gene in carcinogenesis and immune environment monitoring in human cervical cancer.

Abstract

Background15-Hydroxyprostaglandin dehydrogenase (15-PGDH, gene symbol HPGD) is considered a tumor suppressor, and its expression is often proportional to the anticancer response. However, the clinical significance of HPGD/15-PGDH in predicting immune response and its diagnosis and prognosis value in cervical cancer remains unclear.ObjectiveThis study aims to explore the clinical significance of HPGD/15-PGDH in predicting carcinogenesis, prognosis, and sensitivity to immuno- and chemotherapy in cervical cancer.MethodsA comprehensive evaluation of the diagnostic, treatment-sensitive, and prognostic value of HPGD/15-PGDH in cervical cancer was conducted by bioinformatics analysis of public databases and validation of real cohort data.ResultsBioinformatics analysis showed that HPGD expression was decreased in cervical cancer and did not independently predict patient prognosis. Low HPGD expression was linked to resistance to certain chemotherapies, potentially due to immunosuppression triggered by low HPGD levels. Validation in clinical samples from the local hospital confirmed the decreased 15-PGDH expression and increased COX-2 expression in HPV16-positive cervical cancer patients and increased immune suppression during cancer progression.ConclusionsHPGD/15-PGDH is a potential biomarker for predicting the progression, immune response, and chemotherapy sensitivity of cervical cancer, with implications that it is of great value for the diagnosis and individual-based treatment of cervical cancer.